-
Mashup Score: 13
AbstractBackground and aims. The PARAGLIDE-HF trial demonstrated reductions in natriuretic peptides with sacubitril/valsartan compared with valsartan in patient
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 2Quality of Care and Outcomes Among Patients Hospitalized for Heart Failure in Rural vs Urban US Hospitals - 1 year(s) ago
This cohort study assesses quality of care and clinical outcomes for US patients hospitalized for heart failure at rural vs urban hospitals in the Get With The Guidelines–Heart Failure registry.
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet-
In this large contemporary cohort of US patients hospitalized for HF, patients at rural hospitals were less likely to receive multiple elements of guideline-directed HF care, such as #CRT, #ACEI/#ARB, and #ARNI therapies https://t.co/ncIVNV8q5r #HeartFailure @JAMACardio… https://t.co/JWtKHGtCv3 https://t.co/kEzYM6JqMx
-
-
Mashup Score: 1Comparative Risk of Angioedema With Sacubitril-Valsartan vs Renin-Angiotensin-Aldosterone Inhibitors - 1 year(s) ago
Data on angioedema risk among sacubitril-valsartan (SV) users in real-world settings are limited.We sought to evaluate the risk of angioedema among SV…
Source: www.sciencedirect.comCategories: Cardiologists, Latest HeadlinesTweet-
🔥 In this 🇺🇸 study a strategy based on direct start of #ARNI vs the “switching strategy from an #ACEi/#ARB” resulted in a significantly ⬇️ of #angioedema 👉 #ARNI immediate start not only is more effective but also safer 🍀 @gcfmd @JJheart_doc @iamritu https://t.co/tFywymYdMi https://t.co/k3ck77xivT
-
-
Mashup Score: 9Comparative Risk of Angioedema With Sacubitril-Valsartan vs Renin-Angiotensin-Aldosterone Inhibitors: - 1 year(s) ago
Abstract Background Data on angioedema risk among sacubitril-valsartan (SV) users in real-world settings are limited. Objectives We sought to evaluate the risk of angioedema among SV new users comp…
Categories: Cardiologists, Latest HeadlinesTweet-
Comparative Risk of Angioedema With Sac/Val vs #RAAI This study did not observe increased angioedema risk for Sac/Val users compared with #ACEI users, and there was no difference in risk when Sac/Val users were compared with #ARB users https://t.co/nuH0qtuab5 @JACCJournals https://t.co/bB7Uxkyw39 https://t.co/98fnhhV1gI
-
-
Mashup Score: 0
Rosalie A. ScholtesRosalie A. Scholtes Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, Location VUMC, the Netherlands (R.A.S., A.C.H., C.M.M., D.H.v.R.). , Anne C. HespAnne C. Hesp Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, Location VUMC, the Netherlands (R.A.S., A.C.H., C.M.M., D.H.v.R.). , Frank…
Source: CirculationCategories: Cardiologists, Latest HeadlinesTweet-
Kidney Hemodynamic Effects of #ARB, #SGLT2i Alone, and Their Combination in #T2DM This #RCT demonstrates that #SGLT2i combined with #RASi has additional beneficial kidney hemodynamic effects compared with either of the drugs alone in #T2DM https://t.co/dhZLwIdcka @CircAHA https://t.co/MbWXge33BQ
-
-
Mashup Score: 0Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials - PubMed - 2 year(s) ago
Marfan Foundation, the Oxford British Heart Foundation Centre for Research Excellence, and the UK Medical Research Council.
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet-
Interesting and potentially practice changing. I've been using EITHER #BB or #ARB for #Marfans and other aortopaties. Perhaps this is a situation in which BOTH is better? Differing mechanisms would explain. @ShelbyKuttyMD @HopkinsMedicine @drelisabradley https://t.co/jZFp91XKkQ
-
-
Mashup Score: 0
In clinical trials, sacubitril/valsartan has demonstrated significant survival benefits compared to angiotensin converting enzyme inhibitors or angiot…
Source: www.sciencedirect.comCategories: Cardiologists, Latest HeadlinesTweet-
Sa/Val Vs ACEI/ARB at hospital discharge and 5-yr survival in older patients with #HFrEF The benefit of Sa/val over #ACEI/#ARB did not decrease with increasing age – NNT to treat among 66 to 74-yr-old patients was 84 and among 85+ year-old pts was 67 https://t.co/CFxru2w0np
-
-
Mashup Score: 0
New kidney research from the University of Virginia School of Medicine is raising concerns that long-term use of drugs commonly prescribed to treat high-blood pressure and heart failure could be contributing to kidney damage.
Source: News-Medical.netCategories: Healthcare Professionals, Latest HeadlinesTweet-
Nota bene: https://t.co/qK7pJ8bx6F #ARB #ACEi #bloodpressure
-
-
Mashup Score: 23Re-emergence of heart failure with a normal ejection fraction? - 2 year(s) ago
This editorial refers to ‘Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction’, by J. Butler et al.
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
Re-emergence of HF with a normal EF? in #EHJ by #Kondo & #McMurray. Do treatment effects of #SGLT2i attenuate at higher #LVEF similar to #ARB #ARNI #MRA & #digitalis? Stay tuned for #DELIVER in '22 evaluating dapa in 6,263 pts, incl 1,892 with LVEF≥60%. https://t.co/iiiYIECbrL https://t.co/3UrKrBXzto
-
-
Mashup Score: 9
Despite advances in the prevention and treatment of CVD, it remains the leading cause of death in women and men worldwide. Additionally, the absolute burden of CVD mortality in the U.S. is higher in women than in men.The underlying reasons for the observed health disparity between men and women are complex and reflect disparities in risk factor awareness, prevention and optimal medical treatment.
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Findings published in @HyperAHA found #ARB use does not differ significantly from #ACEinhibitor use but does present with a better safety profile in treating patients with #hypertension @ColumbiaCardio @ColumbiaMed #CardiOTwitter https://t.co/70Ll1lAI5r
-
The Lancet commissioned an international group of experts to provide a global assessment of the inequities in CVD care in women and provide focused recommendations @rblument1 @andygagel @garimavsharmamd @anjali_wagle @CiccaroneCenter #CardioTwitter https://t.co/70Ll1lAI5r
-
🔥 Another proof of benefit of #ARNI in #HFmrEF & #HFpEF especially after a recent #HF 🏥 ❤️🔥 #ARNI is more effective in ⬇️ Total #HF events + #CV ☠️ 🍀 #ARNI is safer (safer!) than #ARB about #renal events & function & #hyperk+ https://t.co/T7oWyKbHOT @mvaduganathan @gcfmd https://t.co/Y9yveFF9l7 https://t.co/CVohy6ptnz